Financials data is unavailable for this security.
View more
Year on year AbbVie Inc 's revenues fell -6.44% from 58.05bn to 54.32bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 11.84bn to 4.86bn, a -58.91% decrease.
| Gross margin | 66.65% |
|---|---|
| Net profit margin | 9.73% |
| Operating margin | 22.31% |
| Return on assets | 3.86% |
|---|---|
| Return on equity | 53.93% |
| Return on investment | 5.27% |
More ▼
Cash flow in USDView more
In 2023, AbbVie Inc increased its cash reserves by 39.27%, or 3.61bn. The company earned 22.84bn from its operations for a Cash Flow Margin of 42.05%. In addition the company used 2.01bn on investing activities and also paid 17.22bn in financing cash flows.
| Cash flow per share | 7.83 |
|---|---|
| Price/Cash flow per share | 24.56 |
| Book value per share | 3.84 |
|---|---|
| Tangible book value per share | -49.18 |
More ▼
Balance sheet in USDView more
| Current ratio | 0.8068 |
|---|---|
| Quick ratio | 0.7061 |
| Total debt/total equity | 10.42 |
|---|---|
| Total debt/total capital | 0.9119 |
More ▼
Growth rates in USD
Year on year, growth in dividends per share increased 4.96% while earnings per share excluding extraordinary items fell by -58.97%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 4.08% |
|---|---|
| Div growth rate (5 year) | 10.52% |
| Payout ratio (TTM) | 205.70% |
| EPS growth(5 years) | -6.05 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -38.51 |
More ▼
